

Permacyl 236.3 mg/ml Powder and Solvent for Suspension for Injection for Cattle

Authorised

- Penethamate hydriodide

Product identification

Medicine name:

PERMACYL Powder and solvent for suspension for injection for cattle

Permacyl 236.3 mg/ml Powder and Solvent for Suspension for Injection for Cattle

Active substance:

Penethamate hydriodide

Target species:

Cattle (lactating cow)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Penethamate hydriodide

236.30 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Powder and solvent for suspension for injection

Withdrawal period by route of administration:**Intramuscular use:**

•

Cattle (lactating cow)

- Meat and offal. 4 day
- Milk. 60 hour

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CE90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Available in:

United Kingdom (Northern Ireland)

Package description:

box containing 10 x 10,000,000 IU powder vial and 10 x 36 ml solvent vial
box containing 5 x 10,000,000 IU powder vial and 5 x 36 ml solvent vial
box containing 1 x 10,000,000 IU powder vial and 1 x 36 ml solvent vial
box containing 10 x 5,000,000 IU powder vial and 10 x 18 ml solvent vial
box containing 5 x 5,000,000 IU powder vial and 5 x 18 ml solvent vial
box containing 1 x 5,000,000 IU powder vial and 1 x 18 ml solvent vial

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Divasa Farmavic S.A.

Marketing authorisation date:

18/08/2015

Manufacturing sites for batch release:

DIVASA-FARMAVIC, S.A.-GURB-VIC

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 33229/4005

Date of authorisation status change:

6/07/2018

Reference member state:

Spain

Procedure number:

ES/V/0227/001

Concerned member states:

Austria Belgium Bulgaria Czechia Denmark France Germany Greece
Hungary Ireland Italy Lithuania Netherlands Norway Poland Portugal
Romania Slovakia Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to

www.adrreports.eu/vet